Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

Vaccine. 2017 Jul 13;35(32):4022-4028. doi: 10.1016/j.vaccine.2017.05.062. Epub 2017 Jun 16.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Equivalence Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / blood
  • Antibodies, Viral / blood
  • Diphtheria-Tetanus-Pertussis Vaccine / adverse effects
  • Diphtheria-Tetanus-Pertussis Vaccine / therapeutic use*
  • Female
  • Haemophilus Vaccines / adverse effects
  • Haemophilus Vaccines / therapeutic use*
  • Hepatitis B Vaccines / adverse effects
  • Hepatitis B Vaccines / therapeutic use*
  • Humans
  • Immunogenicity, Vaccine*
  • Infant
  • Male
  • Poliovirus Vaccine, Inactivated / adverse effects
  • Poliovirus Vaccine, Inactivated / therapeutic use*
  • Republic of Korea
  • Standard of Care
  • Vaccines, Combined / adverse effects
  • Vaccines, Combined / therapeutic use

Substances

  • Antibodies, Bacterial
  • Antibodies, Viral
  • DTaP-IPV-HB-PRP-T vaccine
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines
  • Hepatitis B Vaccines
  • Poliovirus Vaccine, Inactivated
  • Vaccines, Combined